Jubilant Generics, a subsidiary of Jubilant Life Sciences, has launched remdesivir for injection called ‘JUBI-R’ in the Indian market. JUBI-R will come at a price of Rs. 4,700 per vial of 100 mg (lyophilized injection).
Jubilant Generics with the help of its distribution network aims to provide the drug to over 1,000 COVID-19 specialized hospitals in India.
Jubilant & Gilead Agreement
In May 2020, when the coronavirus outbreak was on its peak Jubilant Life Sciences entered into a non-exclusive licensing agreement with Gilead Sciences. After the agreement, Jubilant got its right to register, manufacture, and sell Gilead’s drug, Remdesivir.
At that time Jubilant promised to manufacture and sell the drug in 127 countries, including India. The list of 127 countries mainly consists of almost all low-income and lower-middle-income countries, as well as several upper-middle and high-income countries across the world.
What is a non-exclusive licensing agreement?
In a non-exclusive licensing agreement the licensee gets a right to use the registered property, however, the licensor remains free to use the registered intellectual property and also to allow N-number of licensees to use the same registered property.
- To date, Remdesivir is a potential therapy for COVID-19.
- It is the only antiviral drug that has received a green signal for Emergency Use Authorization (EUA) by the USFDA for the treatment in the severe cases of COVID-19.
- Remdesivir is the key ingredient in ‘JUBI-R’. however, ‘JUBI-R’ can only be used in emergency cases with the high supervision of the medical practitioner.
“It gives us immense satisfaction to launch ‘JUBI-R’ as this drug has the potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet the high demand for the drug in the Indian market and other countries,” Shyam S. Bhartia the Chairman and MD and Hari S. Bhartia the Co-Chairman of Jubilant Pharma Limited said in the conference.